Tag Archive for: Genomic

KRAS mutations in Breast cancer may be treatable

/0 Comments/in /by

For decades, mutations in #KRAS have been known to cause cancers in multiple organs and the gene KRAS itself was considered ‘undruggable’. Of the many mutations, KRAS-G12C is known to occur in nearly 13% of #NSCLC cases. There were no known treatments that can target KRAS-G12C mutation until recently. May 2021 heralded the #fdaapproval of Sotorasib, granted to #amgen, for treatment of #lungcancer with the G12C mutation in KRAS. Exciting results showed a reduction in tumour burden in more than 37% of the trial participants. This paves the way for testing the efficacy of the drug in multiple other cancers harbouring this driver mutation.
Our data identified nearly 7.8% of breast cancer #FFPE samples bearing the KRAS-G12C mutation, bringing hope of this #drug to people with #breastcancer.

Mutations in Lung Cancer Driving Targeted Therapy

/0 Comments/in /by

In recent years, personalized medicine has begun to bring new hope to people with lung cancer, especially non-small cell lung cancer. Personalized medicine involves looking at the cells obtained from a biopsy to see if there are any genetic mutations — changes in your genes — that could be linked to the type of cancer you have. Because certain chemotherapy drugs are either more or less effective than others against tumors with specific mutations, molecular analysis of your tumor, also called genomic testing, can help determine which therapies will be most likely to benefit you. The most common genetic changes that are tested for in lung cancer are in the genes EGFR, ALK, ROS, PDL 1 and KRAS.

Kidney cancer rarely affects children. The most common one is Wilms’ tumor, also called nephroblastoma, that accounts for up to 95% of childhood kidney cancers, with most children being below the age of 5 years. It is a fast growing tumor that can spread (metastasize). It is usually treated by surgery, followed by radiation and chemotherapy. Commonly used chemo drugs are doxorubicin, vincristine and actinomycin D. Overall survival rates tend to be high (>90%), with favourable histopathology diagnosis and timely treatment.

/0 Comments/in /by

 

https://www.indiacancersurgerysite.com/wilms-tumor-treatment-india.html